Forest Laboratories, Inc. FRX and Forest Laboratories Holdings,
Ltd. (collectively, “Forest”) announced that Forest and Royalty Pharma
Collection Trust (“Royalty Pharma”) have jointly filed an additional
lawsuit in the U.S. District Court for the District of Delaware against
First Time US Generics LLC (“First Time”) for infringement of U.S.
Patent No. 6,602,911 (“the ‘911 patent”), U.S. Patent No. 7,888,342
(“the ‘342 patent”), and U.S. Patent No. 7,994,220 (“the ‘220 patent),
which relate to Forest's SAVELLA® product. Forest licenses
the ‘911 patent, the ‘342 patent, and the ‘220 patent from Royalty
Pharma. The ‘911 patent expires in January 2023, the ‘342 patent expires
in November 2021, and the ‘220 patent expires in September 2029.
Forest
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in